AR113254A1 - IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE - Google Patents

IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE

Info

Publication number
AR113254A1
AR113254A1 ARP180102629A ARP180102629A AR113254A1 AR 113254 A1 AR113254 A1 AR 113254A1 AR P180102629 A ARP180102629 A AR P180102629A AR P180102629 A ARP180102629 A AR P180102629A AR 113254 A1 AR113254 A1 AR 113254A1
Authority
AR
Argentina
Prior art keywords
angptl3
irna agents
compositions
methods
agents
Prior art date
Application number
ARP180102629A
Other languages
Spanish (es)
Inventor
So Wong
Rui Zhu
Zhen Li
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of AR113254A1 publication Critical patent/AR113254A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a agentes de iARN, por ejemplo, agentes de iARN de cadena doble, capaces de inhibir la expresión del gen de la Angiopoyetina tipo 3 (también denominada ANGPTL3, ANGPL3, proteína angiopoyetina tipo 3), y composiciones que incluyen agentes de iARN de ANGPTL3. También se divulgan métodos para usar los agentes de iARN de ANGPTL3 y composiciones. Los agentes de iARN de ANGPTL3 divulgados en la presente pueden estar conjugados con ligandos de direccionamiento para facilitar la administración a células, inclusive a hepatocitos. También se describen composiciones farmacéuticas que incluyen uno o más agentes de iARN de ANGPTL3, opcionalmente con uno o más productos terapéuticos adicionales. La administración de los agentes de iARN de ANGPTL3 in vivo proporciona la inhibición de la expresión del gen ANGPTL3, y puede dar como resultado niveles de triglicéridos y/o niveles de colesterol reducidos en el sujeto. Los agentes de iARN se pueden usar en métodos de tratamiento de enfermedades y trastornos relacionados con ANGPTL3 que incluyen enfermedades cardiovasculares, tales como hipertrigliceridemia e hiperlipidemia.The present disclosure relates to iRNA agents, eg, double-stranded iRNA agents, capable of inhibiting the expression of the Angiopoietin type 3 gene (also referred to as ANGPTL3, ANGPL3, angiopoietin protein type 3), and compositions including agents iRNA of ANGPTL3. Methods for using the ANGPTL3 iRNA agents and compositions are also disclosed. The ANGPTL3 iRNA agents disclosed herein may be conjugated with targeting ligands to facilitate delivery to cells, including hepatocytes. Also disclosed are pharmaceutical compositions that include one or more ANGPTL3 iRNA agents, optionally with one or more additional therapeutics. Administration of ANGPTL3 iRNA agents in vivo provides for inhibition of ANGPTL3 gene expression, and can result in reduced triglyceride levels and / or cholesterol levels in the subject. IRNA agents can be used in methods of treating ANGPTL3-related diseases and disorders including cardiovascular diseases, such as hypertriglyceridaemia and hyperlipidemia.

ARP180102629A 2017-09-14 2018-09-14 IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE AR113254A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762558819P 2017-09-14 2017-09-14

Publications (1)

Publication Number Publication Date
AR113254A1 true AR113254A1 (en) 2020-03-11

Family

ID=70465584

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102629A AR113254A1 (en) 2017-09-14 2018-09-14 IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE

Country Status (1)

Country Link
AR (1) AR113254A1 (en)

Similar Documents

Publication Publication Date Title
ECSP20018305A (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE
ECSP20017905A (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
CO2018003678A2 (en) Compositions and methods to inhibit lpa gene expression
CO2017004728A2 (en) Compositions and methods to inhibit the expression of the hao1 gene (hydroxy acid oxidase 1 (glycolate oxidase)
CL2016003041A1 (en) Isolated double stranded ribonucleic acids, pharmaceutical compositions comprising them and method for inhibiting the expression of the alas1 gene based on the administration of said composition. divisional application 2725-2014.
EA201692318A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE
ECSP20000655A (en) IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENaC AND METHODS OF USE
AR113254A1 (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE
AR113014A1 (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
AR113454A1 (en) IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1
AR106227A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)
AR112754A1 (en) IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF a-ENaC AND METHODS OF USE
CR20200117A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
EA202090687A1 (en) RNAi AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
AR104542A1 (en) COMPOSITIONS OF ARNi AGAINST FACTOR XII (HAGEMAN FACTOR) (F12), CALICREIN B, PLASMATIC (FLETCHER FACTOR) 1 (KLKB1), AND QUININOGEN 1 (KNG1) AND METHODS OF USE OF THE SAME
AR109293A1 (en) IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS